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Rewiring cellular metabolism is a key hallmark of cancer. Multiple evidences 
show that alterations in various metabolic circuits directly contribute to the tumori-
genic process at different levels (e.g. cancer initiation, metastasis, resistance). 
However, the characterization of the metabolic profile of Neurofibromatosis type 
1 (NF1)-related neoplastic cells has been only partially elucidated both in benign 
neurofibromas and in malignant peripheral nerve sheath tumors (MPNSTs). Here, 
we illustrate the state of the art on the knowledge of the metabolic features of 
tumors related to NF1 and discuss their potential implications for the development 
of novel therapeutic perspectives.
Keywords: NF1, metabolism, mitochondria, chaperones, sirtuins, MPNST, 
neurofibroma, glucose, glutamine, PET
1. Introduction
Neurofibromatosis type 1 (NF1) is a genetic multisystem disorder that  
predisposes to the onset of several tumor types and is characterized by a number 
of clinical manifestations encompassing café au lait macules in the skin, iris 
hamartomas (Lisch nodules), cognitive deficits, axillary or groin freckles, bone 
deformities, optic gliomas and Schwann cell neoplasms called neurofibromas. The 
presence of two or more of these clinical features is used as consensus diagnostic 
criteria for NF1 [1].
NF1 is inherited in an autosomal dominant way when inactivating mutations 
occur at the NF1 locus that encodes for the Ras-GTPase activating protein (Ras-
GAP) neurofibromin. Complete loss of neurofibromin activity, caused by second 
hit mutations, leads to hyperactivation of Ras signaling and tumor onset. The 
tumor type that hallmarks this genetic disease is neurofibroma, a benign neoplasm 
affecting peripheral nerves. Plexiform neurofibromas (PNs) involve perineural 
sheaths of nerve bundles and may occasionally transform into malignant peripheral 
nerve sheath tumors (MPNSTs), highly aggressive sarcomas endowed with a dismal 
prognosis. MPNSTs are currently untreatable, while only recently an inhibitor of 
MEK, a downstream effector of Ras signaling, has been approved for pediatric 
inoperable neurofibromas [2].
PN monitoring is critical for managing tumor progression and early malignancy 
diagnosis. To this purpose, imaging tools are extremely important in identify-
ing suspicious lesions, and an increase in the avidity for the radioactive tracer 
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18F-fluorodeoxyglucose (FDG) during Positron Emission Tomography (PET) scans 
is a critical indication of malignant progression [3–5]. This increase in glucose 
uptake denotes that some neoplastic cells inside the PN mass are undergoing a 
metabolic rewiring. Glucose is used by various intracellular metabolic pathways for 
the overall energetic and anabolic needs of highly proliferative cells, as it provides 
them with several advantages, such as induction of nucleotide and amino acid bio-
synthetic pathways that stem from glycolysis intermediates, as well as enhancement 
of anti-oxidant defenses by boosting the pentose phosphate pathway [6]. Moreover, 
glycolysis induction is often accompanied by a repression in cellular respiration, 
aka oxidative phosphorylation (OXPHOS), making neoplastic cells less dependent 
on oxygen, as its availability can often be scarce in a growing neoplastic mass 
that is poorly vascularized [7]. The characterization of tumor metabolic features 
has gained increased attention in the attempt of identifying crucial regulators of 
metabolism that could be exploited as pharmacological targets.
2. Metabolic features of NF1 patients
Several indications suggest that dysregulation of Ras signaling in NF1 has meta-
bolic effects. Indeed, metabolic alterations have been identified in NF1 patients at 
the systemic level (Figure 1). For instance, in fasting conditions they show a glucose 
level in the blood that is lower than in control people [8] and display an increased 
insulin sensitivity [9] that makes them less prone to diabetes mellitus development 
[10]. This could be caused by a general imbalance in the levels of several hormones, 
including lower levels of leptin and visfatin and higher adiponectin in NF1 patients 
with respect to control subjects. It remains to be explained the mechanistic con-
nection between heterozygous loss of neurofibromin and these metabolic changes, 
confirmed in a large cohort of patients [11]. Moreover, NF1 individuals show 
reduced cerebral glucose metabolism, specifically in the thalamus [12]. Altogether, 
these observations put forward the hypothesis that neurofibromin haploinsuf-
ficiency may have systemic effects in overall glucose utilization. Thalamic glucose 
hypometabolism could be related to the neurological symptoms of NF1 (e.g. 
cognitive impairment). By using NF1 animal models it was also proposed that 
other dysmetabolic traits, such as disarrangements in neuronal usage of glutamate, 
γ-amino butyric acid (GABA) and dopamine, could be connected to the deficits in 
spatial learning, memory and attention observed in patients [13–15].
Changes in the levels of these neurotransmitters could affect the activity of 
several ion channels linked to the neurologic phenotype of NF1. For instance, aug-
mented activity of voltage-gated sodium and calcium channels in sensory neurons 
dictates increased excitability and firing properties and underlies heightened pain 
sensations in NF1 patients [16]. In addition, changes in ion channel properties 
have repercussions on non-neuronal cells in NF1 and may participate in the overall 
alteration of ion homeostasis, as for Ca2+ signaling, which is altered in NF1 kera-
tinocytes [17]. Ca2+ is a highly compartmentalized ion, and its mobilization has 
the capability of tuning a variety of cellular processes connected to mitochondrial 
metabolism and cell death pathways. Whether these Ca2+ alterations in neurofibro-
min haploinsufficient cells install adaptations that are relevant also in NF1-related 
tumors is an intriguing possibility.
At the muscular level, NF1 children may display reduced muscle function, which 
has been related to a role of neurofibromin in regulating fatty acid metabolism 
in this tissue [18]. Muscle specimens from limb-specific Nf1Prx1−/− conditional 
knockout mice show a 10-fold increase in muscle triglyceride content, upregula-
tion in the activity of oxidative metabolism enzymes and increased expression of 
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fatty acid synthase and of the hormone leptin, whereas the expression of a number 
of fatty acid transporters is decreased. This genetic NF1 mouse models has shown 
that a lipid storage disease phenotype may underlie muscle weakness in NF1, thus 
displaying commonalities with the lipid storage myopathies (LSMs), which also 
present with progressive muscle weakness and muscle lipid accumulation, and may 
occasionally be treated with high dose L-carnitine supplementation [19]. Nf1 null 
muscle specimens are enriched in long chain fatty acid (LCFA) containing neutral 
lipids, such as cholesterol esters and triacyl glycerides, suggesting impaired LCFA 
metabolism [20]. Thus, Nf1Prx1−/− mice recapitulate the human NF1 myopathy 
and lipid storage excess inside muscle fibers, and a dietary intervention of reduced 
LCFAs and enrichment of medium-chain fatty acids with L-carnitine effectively res-
cues lipid accumulation and muscle weakness in knockout mice. These data link NF1 
deficiency to fundamental shifts in muscle metabolism, and provide strong proof of 
principle that a dietary intervention can ameliorate muscle symptoms. On the same 
path, pharmacological intervention with the MEK inhibitor PD0325901 in pregnant 
mice is able to rescue body weight loss and lipid accumulation in the Nf1MyoD−/− 
progeny, suggesting a potential mechanism underlying the NF1-Ras-MAPK 
dependency of altered fatty acid metabolism [21]. Furthermore, a recent work has 
highlighted the requirement of neurofibromin for postnatal muscle growth and 
metabolic homeostasis [22].
Figure 1. 




In NF1 patients, skeletal problems including scoliosis, tibial pseudo-arthrosis 
and short stature are also common. Bone dysplasia is considered linked to min-
eralization defects and is a generalized metabolic bone disease [23]. Indeed, NF1 
patients display a decreased bone mineral density, low levels of serum 25-hydroxy 
vitamin D3, increased osteoporosis and fracture risk [24]. Whether these systemic 
metabolic characteristics (i.e. increased glucose utilization and reduced fat depot 
mass) could affect the timing and type of tumor manifestations remains a puz-
zling issue. Neurofibroma onset and growth are accelerated by the heterozygous 
condition of the tumor microenvironment. Similarly, it could be envisioned that 
circulating factors determined by the peculiar metabolism of NF1 also participate 
in determining the extent of cancer predisposition. Moreover, given the sophis-
ticated regulation and adaptability of human metabolism to external factors, 
the understanding of its potential involvement in NF1-related tumorigenesis 
may shed light on the patient-to-patient variability in the tumor burden of this 
disease.
Take home message. Altogether, these reports underline that NF1 has multi-
system effects from the metabolic point of view. Recently, some of the metabolic 
and morphologic features of humans with NF1 have been fully recapitulated by Nf1 
heterozygous mouse models of the disease [25].
3. Metabolic adaptations of NF1-related tumors
One of the most worrisome features of NF1 disease is the increased susceptibil-
ity of patients to several neoplasms. Beside the presence of neurofibromas, benign 
tumors that hallmark this disorder, gliomas, hematological neoplasms, breast 
cancer, pheochromocytomas, gastrointestinal tumors (GISTs) and MPNSTs may 
develop throughout lifetime. Following the loss of the tumor suppressor gene 
neurofibromin and the subsequent activation of the Ras pathway, several intracel-
lular signaling cascades are rearranged and impact on cellular processes relevant 
to cancer progression (e.g. survival, growth, cell death, metabolism). Beside this 
network of deregulated pathways inside the tumor cell, a variety of inter-cellular 
signals are altered by neurofibromin haploinsufficiency. Neurofibromas show a 
highly heterotypic microenvironment composed mainly by mast cells, macrophages 
and fibroblasts, and neoplastic growth depends on the complex interplay between 
these cell types (Figure 2). For instance, the KIT growth factor is secreted by NF1 
null Schwann cells and acts as a chemo-attractant for NF1 heterozygous mast cells. 
In turn, mast cells produce TGFβ, stimulating heterozygous fibroblasts to increase 
production of collagen and of other extracellular matrix (ECM) proteins. Mast 
cells also produce heparin, vascular endothelial growth factor (VEGF) and matrix 
metalloproteases (MMPs), which promote tumor vascularization and invasiveness. 
Aberrantly proliferating Schwann cells secrete colony-stimulating factor (CSF1), 
thereby recruiting macrophages that sustain tumor progression.
Apart from regulating survival and proliferation, some of these alterations in 
signal transduction can also directly affect cellular metabolism. Indeed, RAS signal-
ing promotes oncogenic metabolism by coordinating numerous metabolic processes 
including lipid, nucleotide, and glycolytic pathways (Figure 2). Specifically, 
upregulation of the Ras pathway sustains a glycolytic and glutaminolytic metabo-
lism by MYC induction, allowing cancer cells to preferentially use glucose and glu-
tamine for anabolic purposes. This is accompanied by a decrease in OXPHOS that 
is characterized by blunted TCA cycle and reduced mitochondrial respiration. Ras 
downstream pathways, such as the mTOR signaling, also affect lipid and nucleotide 
synthesis for anabolic demands [26, 27].
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Several metabolic circuits converge on mitochondria, which are considered the 
powerhouse of the cell. They are in charge of energy supply and actively sustain 
biosynthetic pathways mandatory for cell replication. Moreover, mitochondria 
are involved in cell death signaling and contribute to oxidative stress regulation. 
Changes in several mitochondrial functions have been linked to the pro-neoplastic 
dysregulation of many fundamental biological processes, including a variety of 
bioenergetic circuities [28].
Tumor metabolism refers to a plethora of cancer features, spanning from the 
way neoplastic cells take up and utilize nutrients for growth and replication, to the 
diverse communication modes they establish with the neighboring cells. Altogether, 
these metabolic adaptations during cancer initiation and progression render aber-
rant cells capable of circumventing nutrient and oxygen shortage conditions that 
they may encounter, and often affect and constrain the behavior of the surrounding 
microenvironment [29].
So far, targeting strategies against cancer mainly rely on specifically blocking 
molecular signals that promote cell proliferation, hinder cell death, modulate the 
immune response or enhance angiogenesis and cell survival. However, most of 
these signaling pathways are either redundant or essential in healthy tissue making 
these types of target therapies challenging. A further strategy is to hit key metabolic 
transformations that occur in cancer cells, whereby the metabolic adaptations to 
hypoxic conditions seem to be specific for cancer cells, shared in many tumor types 
and required for neoplastic growth.
3.1 Mitochondrial respiration
Although the metabolic scenario of NF1 mutant cells is poorly defined, some 
bioenergetic alterations are starting to surface. For instance, respiratory complex II, 
Figure 2. 
Impact of neurofibromin loss on intra/intercellular signaling and metabolic pathways. Signaling cascades 
within Schwann cells and in the heterozygous microenvironment are highlighted in black. Metabolic pathways 
altered following neurofibromin loss are depicted in red.
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aka succinate dehydrogenase (SDH), is a crucial metabolic enzyme at the crossroad 
between OXPHOS and Krebs cycle that is repressed in NF1-related tumor cells in 
an ERK-dependent manner following neurofibromin loss; this metabolic rewiring 
is compensated by an increased glycolytic pathway [30]. In detail, hyperactivation 
of the mitochondrial branch of Ras/ERK signaling causes phosphorylation of the 
mitochondrial chaperone TRAP1. Its consequent activation inhibits SDH enzymatic 
activity, triggering intracellular accumulation of the oncometabolite succinate 
that in turn stabilizes the pro-neoplastic transcription factor HIF1α. Importantly, 
genetic ablation of TRAP1 inhibits tumor growth [31]. Taken together, these data 
indicate that TRAP1 mediates a pseudo-hypoxic signaling, as it orchestrates a 
HIF1α-dependent program that is crucial in the neoplastic process and boosts tumor 
growth independently of environmental oxygen tension. Moreover, it was recently 
demonstrated that TRAP1 also executes the hypoxic response, as it is a transcrip-
tional target of HIF1α induced in KRAS-dependent models of carcinogenesis, such 
as pancreatic adenocarcinoma, with a crucial role in handling the cell bioenergetic 
response to oxygen paucity [32]. In specific cases of familiar cancers (i.e. in the 
hereditary paraganglioma-phaeochromocytoma syndrome, HPGL/PCC), succinate 
increases following inactivating mutations of SDH subunits. In these settings, in 
addition to inducing HIF1α, high levels of succinate can impinge on cell epigenetics 
by inhibiting α-ketoglutarate dependent dioxygenases, such as histone and DNA 
demethylases, further contributing to neoplastic growth [33]. Therefore, it can be 
envisioned that similar complex changes in the epigenome landscape occur upon 
TRAP1-mediated SDH inhibition in NF1-related tumor cells.
As a consequence, pharmacological inhibition of TRAP1 has been proposed as an 
anti-neoplastic approach for MPNST and other tumor types. Recently, the identifica-
tion of highly selective TRAP1 allosteric inhibitors has shown promising results, 
ablating in vitro tumorigenesis [34, 35]. Previous targeting of the HSP90 family of 
chaperones, to which TRAP1 belongs, has been pursued with the drug IPI-504 which, 
in combination with the mTOR inhibitor rapamycin, cooperates in the growth repres-
sion of NF1 mutant cancer cells [36]. Here, strong ER stress drastically represses 
cancer growth. Given the intense molecular crosstalk between ER and mitochondria 
and their coordinated regulation of Ca2+ homeostasis, it could be envisaged that the 
interplay between ER and mitochondria is crucial in the growth of NF1 deficient cells. 
Indeed, yeast synthetic lethality screens have identified Y100 as a molecule capable of 
interfering with mito-ER homeostasis, thus revealing crucial metabolic vulnerabilities 
of the yeast cells null for the homolog of NF1, called IRA2 [37].
Another report describes that neurofibromin-deficient cells display a decrease 
in the activity of NADH dehydrogenase, aka the first respiratory complex, with 
a consequent unbalance in NAD+/NADH ratio [38]. This metabolic alteration 
negatively impacts on the activity of mitochondrial sirtuins, specifically SIRT3. 
SIRT3 reactivation through NAD+ precursor supply or genetic manipulation impairs 
tumorigenesis of neurofibromin-deficient cells and synergize with TRAP1 abla-
tion in repressing MPNST growth in xenografts by preventing HIF1α stabilization. 
Furthermore, the repressed expression of several subunits of the NADH dehydro-
genase respiratory complex I, one of the main ROS producers in mitochondria, 
renders neurofibromin-deficient cells more resistant to pro-oxidant drugs acting 
through complex I-mediated ROS increase.
Take home message. Altogether, these data indicate that NF1-related tumors 
display a pseudo-hypoxic signature that contributes to tumor proliferation and 
transition towards malignancy. Indeed, neurofibromin inactivation occurs in 
certain cancers through hypoxia-induced degradation, independently of NF1 gene 
mutations [39]. These data suggest that the hypoxic response might affect the 
Ras/ERK signaling pathways downstream to neurofibromin loss and its genetic 
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inactivation installs a hypoxic-like response that may provide cells with an equipped 
and prompt response to any possible drop in oxygen availability.
3.2 Glutamine metabolism
As already shown for several cancers, NF1 null cells are highly sensitive to gluta-
mine deprivation, and glutaminase (GLS) inhibitors such as BPTES (bis-2-(5-phen-
ylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3) or CB-839 have been proposed as 
antineoplastic agents in the context of NF1-associated neoplasms [40]. Glutamine 
is one of the most abundant intracellular amino acids and fuels several biosynthetic 
pathways by providing carbons to TCA cycle intermediates, glutathione, fatty acids, 
and nucleotides. Pharmacological GLS inhibition causes a shortage in multiple TCA 
cycle intermediates, among which α-ketoglutarate, succinate and fumarate.
Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in patients 
with metastatic or unresectable MPNST is ongoing (https://clinicaltrials.gov/ct2/
show/NCT03872427). Still, CB-839 resistance has been observed in vitro, whereby 
c-Myc induction takes place through epigenetic changes mediated by bromodo-
main-containing protein 4 (BRD4), which promotes transcription by recognizing 
acetylated lysines on histones. Indeed, CB-839 resistant cells are more sensitive to 
JQ1, a small molecule inhibitor of BRD4 [41]. Furthermore, glutamine dependency 
has been identified in lung adenocarcinomas where KRAS mutations coexist with 
Nf1 loss [42]. This work suggests that oncologic patient stratification for NF1 loss 
may uncover crucial targetable metabolic adaptations.
Similarly, the glutamine antagonist JHU395, a novel orally bioavailable prodrug 
designed to circulate in an inert form in plasma and to permeate and release the 
active drug within target tissues, is able to inhibit tumor growth in a murine flank 
MPNST model [43]. One of the major outcomes of JHU395 administration is the 
reduced usage of glutamine-dependent metabolites with a prominent effect on 
purine synthesis. Interestingly, glutamine utilization for anaplerotic purposes (i.e. 
supply of TCA intermediates such as glutamate, α-ketoglutarate and succinate) is 
not limited by JHU395. The different modes of action of drugs targeting glutamine 
metabolism indicate that multiple metabolic pathways in glutamine utilization 
might be critical for MPNST growth.
3.3 Lipid metabolism
During cancer growth, transformed cells experience nutrient and glucose short-
age and must install metabolic adaptations to overcome these potentially harmful 
circumstances. Metabolic stress factors such as hypoxia and glucose deprivation 
increase expression of carnitine palmitoyltransferase 1C (CPT1C), member of a 
family of mitochondria-associated enzymes that regulate fatty acid metabolism. 
Its genetic ablation in a NF1 murine model delays tumor growth [44]. This finding 
exposes a susceptibility of NF1-related cancers to drugs targeting lipid metabolism 
when stressful conditions occur, as in the case of active chemotherapeutic regimens.
Lipid droplet accumulation has been reported in MPNSTs, which utilize both 
exogenous and endogenous lipids as a source of energy [45]. Indeed, either disrup-
tion of fatty acid oxidation and the use of the  fatty acid synthase (FASN) inhibitors 
C75, orlistat and Irgasan reduce MPNST survival.
MPNSTs have been reported to secrete elevated levels of prostaglandin E2 
(PGE2), an active lipid compound with hormone-like effects in animals [46]. It 
usually acts as an endocrine mediator of metabolic processes in homeostasis but also 
in inflammatory and neoplastic conditions. Remarkably, PGE2 receptor antagonists 
decreased the proliferation of MPNST cell lines. Prostaglandin administration has 
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also been linked to aberrant cAMP metabolism in MPNSTs that display two-fold 
increased cAMP levels compared to normal Schwann cells [47].
3.4 Connections between genetic mutations and metabolic changes
The HPGL/PCC syndrome, where loss-of-function mutations affect SDH 
and increase intracellular levels of the oncometabolite succinate, thus causing 
onset of pheochromocytoma and paraganglioma, is a proof-of-concept that 
metabolic changes can drive tumorigenesis. It is of note that NF1 patients can 
develop this kind of tumors in 5% of cases, whereas in non-NF1 related patients 
with HPGL/PCC history NF1 mutations have been reported in tumor cells [48]. 
This information, even though only correlative, is in accord with the observa-
tion that TRAP1 exerts a pro-neoplastic role in NF1 by inhibiting SDH, and 
suggests a possible overlapping path of metabolic adaptations existing between 
inactivation of NF1 and SDH components. Moreover, it must be highlighted that 
dysregulated signaling cascades can impinge on metabolic circuits, thus leading 
to neoplastic metabolic alterations either in the absence or in addition to specific 
mutations in metabolic enzymes.
Another interesting line of investigation links gene mutations to pro-neoplastic 
metabolic adaptations during neurofibroma growth. Indeed, it was reported that 
somatic mutations in mitochondrial DNA (mtDNA), which encodes 13 proteins 
of the OXPHOS machinery, are acquired and maintained by a high percentage of 
cutaneous and plexiform neurofibromas [49]. This suggests a possible positive 
selection in neoplastic cells for mutated mitochondrial genes, in keeping with 
observations that an aberrant mitochondrial respiration confers adaptive advan-
tages to neurofibroma cells.
Take home message. Although the metabolic landscape of neurofibromin-
deficient cells and MPNST has been only partially investigated, uncovering the 
adaptations in the metabolic circuits of these tumor cells may shed light on novel 
targetable actors. Furthermore, despite the genetic variability in MPNSTs charac-
terized by different acquired mutations (e.g. TP53, p16, PRC, SUZ12, CDKN2A, 
etc.), there is the possibility of conserved derangements in metabolic pathways that 
may render MPNST vulnerable to selective targeting.
Perspectives. Beside cell autonomous changes in metabolism of neurofibromin-
deficient tumor cells, their metabolic phenotype can be determined by alterations 
in intercellular communication within the tumor microenvironment. Recently it 
has been reported that fibroblast metabolic rewiring can promote growth of neural 
tumors [50]. Furthermore, beside the mitochondria to nucleus signaling mediated 
by succinate-dependent regulation of HIF1α and of epigenetic changes, this onco-
metabolite can exit tumor cells affecting immune cell responses. Thus, metabolic 
changes within neurofibromin null cells can affect the behavior of neighboring 
cells within the tumor microenvironment. Recent advances in immunotherapy 
approaches against MPNST growth have highlighted how these cancers might 
evade immune recognition and hijack immunological functions (e.g. tissue healing, 
angiogenesis, etc.) to their advantage. Whether the metabolic status of NF1-related 
tumors mediate the relationship between transformed cells and immune system is 
an exciting matter of investigation.
4. Conclusions
For a long time, pharmacological treatments suited for NF1-related neoplasms 
have been lacking. Only recently the first therapeutic approaches have been 
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translated from NF1 mouse models to patient bedside and further clinical trials are 
currently ongoing. Altogether, the major efforts in managing NF1-related neo-
plasms have been based on drugs targeting signaling transduction cascades such as 
RTK, RAS- RAF–MEK–ERK and PI3K-AKT–mTOR inhibitors. Selumetinib was the 
first drug approved in 2019 by the US FDA for pediatric NF1 patients with symp-
tomatic and inoperable PN [51, 52] after a phase 2 clinical trial started a decade 
ago (https://clinicaltrials.gov/ct2/show/NCT01362803). Results indicate that 74% 
of patients display a partial response in terms of tumor volume shrinkage, and 
this is durable in 56% of patients. Albeit extremely positive, these results demand 
the urgent development of additional treatments. Previous attempts of targeting 
signaling cascades in neurofibroma microenvironment through imatinib mesylate 
administration, a dual SCF/cKIT inhibitor, have shown modest response rates lim-
ited only to small tumors [53] (https://clinicaltrials.gov/ct2/show/NCT01673009). 
Cabozantinib, an inhibitor of multiple tyrosine kinases among which c-Kit, vascu-
lar endothelial growth factor (VEGF) receptor (VEGFR)2, MET, RET, FMS-related 
RTK 3 (FLT3) and TAM family receptors (tyrosine kinases AXL, TYRO3 and 
MERTK) is now under study in a phase II trial against progressive or symptomatic, 
inoperable PN (https://clinicaltrials.gov/ct2/show/NCT02101736) as it has shown 
promising results in Nf1-mutant mice [54].
As for glioma, chemotherapy remains the first line treatment. More recently, 
epigenetic-based approaches in fighting MPNST growth have emerged [55] and 
drugs targeting the immune checkpoints are considered the emerging therapeutic 
option with ongoing clinical trials [56, 57] (https://clinicaltrials.gov/ct2/show/
NCT02691026).
In this scenario, beside the recently reviewed pharmacological options for 
MPNST treatment [58–60], targeting the metabolic features of NF1-related 
tumors constitutes an additional, promising therapeutic option. Although multiple 
metabolic routes have been shown to be affected in NF1 tumorigenesis, metabolic 
based anti-neoplastic approaches are limited in the field (BeGIN clinical trial) and 
others are at the preclinical stage (Figure 3). A recent report has resumed the idea 
of targeting the glycolytic pathway [61]; however, the drug employed, i.e. 3-bro-
mopyruvate, has already been dismissed from past clinical trials for excessive and 
life-threatening toxicity.
As for MPNST, complete surgical excision with clear margins remains the only 
treatment in the case of a localized cancer. Given the lack of efficacy in targeting 
unique aspects of MPNST disease biology, some benefits could hopefully come 
from combinatorial therapeutic designs that consider and include innovative 
rational therapies, such as targeting bioenergetic circuities.
In this direction, despite the genetically heterogeneous phenotype of NF1-related 
malignancies, the annotation of conserved metabolic adaptations in the progression 
towards MPNST might open space for innovative therapeutic interventions [62].
Perspectives. Advancements in animal modeling of NF1-related neoplasms are 
meant to refine the understanding of PN tumorigenesis and put the basis for testing 
multi-targeted drug therapies and adaptive tumor response. For instance, atypical 
neurofibromas with an uncertain transforming potential have been recapitulated by 
Cdkn2a loss [63]. Uncovering the potential metabolic adaptations of the transitional 
stages of NF1 tumors from the benign to the malignant ones may equip clinicians 
with metabolic biomarkers to be monitored during NF1 patient surveillance.
Furthermore, the understanding of the metabolic interplay between cancer cells 
that have lost neurofibromin and other cell types present in the tumor microen-
vironment might uncover metabolic susceptibility of these cancers. For instance, 
MPNSTs display an increased number of macrophages with respect to PNs and 
are highly glutamine-addicted. It is known that macrophages sense the lack of 
Neurofibromatosis
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glutamine and install a synthetic pathway for glutamine supply based on glutamine 
synthetase induction. This metabolic rewiring characterizes the pro-tumorigenic 
polarization towards a tumor-associated macrophage phenotype. Given these 
tight and crucial metabolic crosstalks between tumor cells and the immunologic 
compartment, it can be envisioned that targeted therapies are accompanied by 
metabolic-based treatments hitting both neoplastic and environmental cells in 
order to overcome potential cancer resistance (e.g. CB-839 and JQ1, which combines 
metabolic and epigenetic treatments).
PET scans with labeled glucose uptake evaluation can provide an extremely 
useful tool for monitoring lesions at high potential for growth and at risk for 
malignant transformation; regular imaging is suggested especially in symptomatic 
neurofibromas [64]. We expect that metabolic tracking of additional nutrients such 
as glutamine could be employed in NF1 patients for the unraveling of metabolically 
active lesions. Imaging of labeled glutamine is currently under evaluations in cancer 
patients and has the potential of predicting cancer response to metabolic targeted 
therapies, thus helping the guidance of therapeutic decision-making [65, 66].
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